Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?

Autoimmunity Reviews

Volumn 9, Issue 8, 2010, Pages 547-552

  Losada, Inès ^a   Sartori, Leonardo ^b   Di Gianantonio, Elena ^b   Zen, Margherita ^b   Clementi, Maurizio ^b   Doria, Andrea ^b  

^a HOSPITAL SON LLÀTZER   (Spain)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autoimmunity; Bisphosphonates; Corticosteroids; Foetus; Osteoporosis; Pregnancy

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; CYCLOSPORIN; ETIDRONIC ACID; HYDROXYCHLOROQUINE; IBANDRONIC ACID; MORPHINE; NERIDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SALAZOSULFAPYRIDINE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ANEMIA; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BIRTH WEIGHT; BONE EROSION; BONE GROWTH; BONE TURNOVER; BREAST FEEDING; CALCINOSIS; CONGENITAL MALFORMATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DERMATOMYOSITIS; DISTRESS SYNDROME; DRUG EXCRETION; DRUG MILK LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; EPISCLERITIS; ESOPHAGITIS; EYE PAIN; FEMALE; FIBROUS DYSPLASIA; FLU LIKE SYNDROME; FRACTURE; GESTATIONAL AGE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MALIGNANT HYPERCALCEMIA; NONHUMAN; ORBITAL PAIN; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PELVIS FRACTURE; PLASMA HALF LIFE; POLYMYOSITIS; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PREMENOPAUSE; PRENATAL DRUG EXPOSURE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOARTHROPATHY; SPONTANEOUS ABORTION; SYMPATHETIC DYSTROPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UVEITIS; VASCULITIS; VISUAL IMPAIRMENT;

ADRENAL CORTEX HORMONES; ANIMALS; AUTOIMMUNE DISEASES; BONE AND BONES; DIPHOSPHONATES; EMBRYO, MAMMALIAN; FEMALE; HUMANS; OSTEOPOROSIS; PREGNANCY; RHEUMATIC DISEASES;

EID: 77952745140     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.03.002     Document Type: Review

References (40)

1. Papapoulos S.E. Bisphosphonates: how do they work?. Best Pract Res Clin Endrocrinol Metab 22 5 (2008) 831-847
2. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Adhoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 44 (2001) 1496-1503
3. Patlas N., Colomb G., Yaffe P., Pinto T., Breuer E., and Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60 (1999) 68-73
4. Sambrook P. Bisphosphonates in corticosteroid-induced osteoporosis. Clinic Rev Bone Miner Metab 5 (2007) 153-158
5. Doria A., Zampieri S., and Sarzi-Puttini P. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 8 2 (2008) 89-91
6. Doria A., Iaccarino L., Ghirardello A., Zampieri S., Arienti S., Sarzi-Puttini P., et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119 (2006) 1497-1499
7. Doria A., Sarzi-Puttini P., and Shoenfeld Y. Infections, rheumatism and autoimmunity: the conflicting relationship between humans and their environment. Autoimmun Rev 8 1 (2008) 1-4
8. Doria A., Arienti S., Rampudda M., Canova M., Tonon M., and Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 7 (2008) 192-197
9. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66 (2007) 1560-1567
10. Olszynski W.P., Adachi J.D., Hanley D.A., Kendler D.L., Hodsman A.B., Siminoski K.G., et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 29 4 (2000) 228-251 Review
11. Sinigaglia L., Varenna M., Binelli L., Zucchi F., Ghiringhella D., Gallazzi M., et al. Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 26 (1999) 1280-1284
12. Ramsey-Goldman R., Dunn J.E., and Cheng Fang H. Frequency of fractures in women with systemic lupus erythematosus. Arthritis Rheum 42 (1999) 882-890
13. Kaji H., Yamauchi M., Chihara K., and Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 53 1 (2006) 27-34
14. Migliaccio S., Brama M., and Malavolta N. Management of glucocorticoid-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag 5 2 (2009) 305-310
15. Tektonidou M.G., Malagari K., Vlachoyiannopoulos P.G., Kelekis D.A., and Moutsopoulos H.M. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use. Arthritis Rheum 48 3 (2003) 732-736
16. Maksmymowych W.P., Lambert R., Jhangri G.S., Leclercq S., Chiu P., Wong B., et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 28 1 (2001) 144-155
17. Recker R., Lewiecki M., Miller P., and Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 122 346 (2009) 22-32
18. Srivastra T., and Alon U.S. The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162 (2003) 735-751
19. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38 (2006) 617-627
20. Russell R.G.G., Watts N.B., and Ebetino F.H. Mechanism of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Oteoporos Int 19 (2008) 733-759
21. Lin J.H., Duggan D.E., Chen I.W.U., and Ellsworth R.L. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dipos 19 (1991) 926-932
22. Hassen-Zrour S., Korbaa W., Bèjia I., and Saidani Z. Maternal and fetal outcome after long-term bisphophonate exposure before conception. Osteoporos Int 21 (2010) 709-710
23. Nolen G.A., and Buehler E.V. The effects of disodium etidronate on the reproductive functions and embryogenesis of albino rats and New Zealand rabbits. Toxicol Appl Pharmacol 18 3 (1971) 548-561
24. Okazaki A., Matsuzawa T., Takeda M., York R.G., Barrow P.C., King V.C., et al. Intravenous reproductive and developmental toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats and rabbits. J Toxicol Sci 20 1 (1995) 1-13
25. Ornoy A., Wajnberg R., and Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronte treatment. Reprod Toxicol 22 (2006) 578-579
26. Levy S., Fayez I., Taguchi N., Han J.H., Aiello J., Matsui D., et al. Pregnancy outcome following in utero exposure to bisphosphonate. Bone 44 (2009) 428-430
27. Rutgers-Verhage A.R., and De Vries T.W. No effects of bisphosphonates on the human foetus. Birth Defects Res A Clin Mol Teratol 67 3 (2003 Mar) 203-204
28. Munns C.F., Rauch F., Ward L., and Glorieux F.H. Maternal and foetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19 10 (2004) 1742-1745
29. Chan B., and Zacharin M. Maternal and infant outcome after pamidronte treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception; a report of four cases. J Clin Endocrinol Metab 91 6 (2006) 2017-2020
30. Illidge T.M., Hussey M., and Godden C.W. Malignant hypercalcemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8 4 (1996) 257-258
31. Culbert E.C., and Schifrin B.S. Malignant hypercalcemia in pregnancy: effects of pamidronate on uterine contractions. Obstet Gynecol 108 (2006) 789-791
32. Dunlop D.J., and Soukop M. Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49 11 (1990) 955
33. Biswas P.N., Witlon L.V., and Shakir S.A.W. Pharmacovigilance study of alendronate in England. Osteopros Int 14 (2003) 507-514
34. Cabar F.R., Nomura R.M., and Zugaib M. Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol 25 2 (2007) 344-345
35. Heino T.J., Chagin A., Takigawa M., and Savendahl L. Effects of alendronate and pamidronate on cultured rat metatarsal bones: failure to prevent dexamethasone-induced growth retardation. Bone 42 (2008) 702-709
36. Koivukangas A., Tuukkanen J., Hannuniemi R., Kioppo K., and Jalovaara P. Effects of long term administration of clodronate on growing rat bone. Calcif Tissue Int 69 (2001) 350-355
37. Antoniazzi F., Zamboni G., Lauriola S., Donadi L., Adami S., and Tatò L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 149 2 (2006) 174-179
38. Bianchi M.L., Cimaz R., Bardere M., Zulian F., Lepore L., Boncompagni A., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. Arthritis Rheum 9 (2000) 1960-1966
39. Brumsen C., Papapoulos S.E., and Hamdy N.A. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 76 4 (1997) 266-283 (Baltimore)
40. Siminoski K., Fitzgerald A.A., Flesch G., and Gross M.S. Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15 10 (2000) 2052-2054